Role of CCN6 (WISP3) in the progression and metastasis of breast cancer
CCN6 (WISP3) 在乳腺癌进展和转移中的作用
基本信息
- 批准号:8305594
- 负责人:
- 金额:$ 29.36万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-09-01 至 2013-07-31
- 项目状态:已结题
- 来源:
- 关键词:Acinus organ componentAddressAnimal ModelAwardBenignBindingBiological AssayBiological MarkersBiologyBreastBreast Cancer CellCancer EtiologyCarcinomaCause of DeathCellsCessation of lifeCharacteristicsClinicalComplexDataDevelopmentDiagnosisDifferentiation and GrowthDistant MetastasisDown-RegulationDrug Delivery SystemsDuctal CarcinomaE-CadherinERBB2 geneEpithelialEpithelial CellsEpitheliumEstrogen Receptor StatusEstrogen receptor positiveExhibitsFamilyFundingGenesGoalsGrowthHistologicIn VitroInsulin-Like Growth Factor IInvadedInvestigationKnockout MiceKnowledgeLaboratoriesLearningLesionMaintenanceMalignant - descriptorMalignant ConversionMalignant NeoplasmsMammary NeoplasmsMammary glandMediatingMetastatic Neoplasm to the BreastMolecularMusNeoplasm MetastasisNodalNoninfiltrating Intraductal CarcinomaOutcomePathogenesisPathway interactionsPatientsPlayPremalignantPreventionProcessProteinsRepressionRoleSamplingSignal PathwaySignal TransductionSignaling ProteinTherapeutic InterventionTissue SampleTransgenic MiceTranslatingTumor Suppressor ProteinsWomanWomen&aposs Healthbasebreast tumorigenesiscancer cellcohortepithelial to mesenchymal transitionfollow-uphuman tissueimprovedin vivoin vivo Modelinflammatory breast cancerloss of functionmalignant breast neoplasmmammary epitheliummembermouse modelmutantnoveloutcome forecastoverexpressionpreventresearch studytissue resourcetumortumor growthtumor progression
项目摘要
ABSTRACT
Breast cancer is the second leading cause of cancer deaths in women and is the most common cancer
among women. The primary cause of death in patients with breast cancer is the development of
metastasis, a process that is still poorly understood. Characterizing genes that regulate the growth and
metastatic ability of breast cancer may identify novel biomarkers to help clinicians guide current
treatments, and may offer new targets for therapy. We have identified CCN6 [WISP3 (Wnt-1 induced
signaling protein 3)] as being down-regulated in tissue samples of breast cancers with high metastatic
ability. CCN6 is a member of the CCN family, which mediate cross-talk between the epithelium and the
stroma and regulate fundamental processes including cellular differentiation and growth. Emerging data
show that CCN proteins are deregulated in cancer. In studies funded by my K08 award, we have begun
to study the role of CCN6 in breast cancer, which was unknown. We showed that CCN6 has tumor
inhibitory functions in breast cancer in vivo and in vitro. We discovered that CCN6 interferes with the
growth effects of IGF-1 and its signaling pathway in the mammary epithelium. Recently, our laboratory
made the novel observation that inhibition of CCN6 in benign breast epithelial cells causes an epithelial
to mesenchymal transition (EMT) with marked down regulation of E-cadherin. Our central hypothesis
is that CCN6 plays a causal role in the pathogenesis of breast cancer. We postulate that loss of
CCN6 in the breast promotes tumor growth, invasion and metastasis by (a) regulating the
growth effects of IGF-1 on the mammary epithelium, and (b) repressing the E-cadherin complex.
CCN6 loss in breast cancer may drive a group of aggressive and metastatic tumors. The specific aims
of this project are as follows: Aim 1: To determine the role of CCN6 in regulating the growth of breast
cancer in vitro and in vivo and its relationship with IGF-1 signaling pathways; Aim 2: To investigate the
biologic implications and the molecular basis of CCN6 mediated epithelial to mesenchymal transition in
breast cancer; Aim 3: To determine whether CCN6 loss accelerates the growth of mammary tumors
and their metastatic potential using well-characterized mouse models of breast tumorigenesis. We will
investigate the effect of CCN6 inhibition on the process of EMT and on IGF-1 signaling in vivo using
unique human tissue resources consisting of samples of normal breast, ductal carcinoma in situ
(DCIS), invasive carcinomas, and nodal and distant metastases. Regulating the expression of CCN6
may represent an important drug target for prevention and cure of breast cancer. These studies have
the potential of providing better diagnosis, more accurate predicting of poor prognosis and open the
potential for new therapies. PROJECT NARRATIVE
Breast cancer is the second leading cause of cancer deaths in women and is the most common cancer among
women. This study addresses an important aspect of women's health, that of how CCN6 regulates the growth
and epithelial differentiation of breast tumors and prevents malignant conversion. If we could prevent the loss
of CCN6 or reactivate it in metastasizing tumors we would greatly improve breast cancer outcome and save
the lives of millions of women. These studies may form the basis of intervention and therapy in breast cancer,
potentially preventing premalignant lesions from becoming malignant and metastasizing.
摘要
乳腺癌是女性癌症死亡的第二大原因,也是最常见的癌症
在女性中。乳腺癌患者死亡的主要原因是
转移,一个仍然知之甚少的过程。表征调控生长的基因,
乳腺癌的转移能力可能会发现新的生物标志物,以帮助临床医生指导当前的
治疗,并可能提供新的治疗目标。我们已经鉴定了CCN 6 [WISP 3(Wnt-1诱导的
信号蛋白3)]在具有高转移性的乳腺癌组织样品中下调
能力CCN 6是CCN家族的一员,其介导上皮和上皮细胞之间的串扰。
基质和调节基本过程,包括细胞分化和生长。新出现的数据
表明CCN蛋白在癌症中失调。在我的K 08奖资助的研究中,
研究CCN 6在乳腺癌中的作用,这是未知的。我们发现CCN 6具有肿瘤
在体内和体外乳腺癌中的抑制功能。我们发现CCN 6干扰了
IGF-1及其信号通路在乳腺上皮细胞中的生长作用。最近,我们的实验室
进行了新的观察,在良性乳腺上皮细胞中抑制CCN 6会导致上皮细胞
向间质转化(EMT)转变,E-cadherin表达显著下调。我们的核心假设
CCN 6在乳腺癌的发病机制中起着因果作用。我们假设,
乳腺中的CCN 6通过以下方式促进肿瘤生长、侵袭和转移:(a)调节CCN 6的表达,
IGF-1对乳腺上皮的生长作用,和(B)抑制E-钙粘蛋白复合物。
乳腺癌中CCN 6的丢失可能会导致一组侵袭性和转移性肿瘤。具体目标
目的1:探讨CCN 6在乳腺发育中的作用
目的2:探讨IGF-1信号通路与肿瘤细胞凋亡的关系,为进一步研究IGF-1信号通路在肿瘤细胞凋亡中的作用奠定基础。
CCN 6介导的上皮细胞向间充质细胞转化的生物学意义和分子基础
乳腺癌;目的3:确定CCN 6缺失是否加速乳腺肿瘤的生长
以及它们的转移潜能。我们将
研究CCN 6抑制对EMT过程和体内IGF-1信号传导的影响,
独特的人体组织资源,包括正常乳腺、导管原位癌
(DCIS)、浸润性癌以及淋巴结和远处转移。调控CCN 6的表达
可能是防治乳腺癌的重要药物靶点。这些研究
为更好地诊断、更准确地预测不良预后和开辟新的治疗途径提供了可能。
新疗法的潜力。项目叙述
乳腺癌是女性癌症死亡的第二大原因,也是女性中最常见的癌症。
妇女这项研究解决了妇女健康的一个重要方面,即CCN 6如何调节生长。
和上皮分化的乳腺肿瘤,并防止恶性转化。如果我们能阻止
或在转移性肿瘤中重新激活它,我们将大大改善乳腺癌的预后,
数百万妇女的生命。这些研究可能成为乳腺癌干预和治疗的基础,
潜在地防止癌前病变恶化和转移。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Celina G Kleer其他文献
Celina G Kleer的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Celina G Kleer', 18)}}的其他基金
The Function of EZH2 in Estrogen Receptor Negative Breast Cancer in Women of Af
EZH2在AF女性雌激素受体阴性乳腺癌中的作用
- 批准号:
8532854 - 财政年份:2010
- 资助金额:
$ 29.36万 - 项目类别:
The Function of EZH2 in Estrogen Receptor Negative Breast Cancer in Women of Af
EZH2在AF女性雌激素受体阴性乳腺癌中的作用
- 批准号:
8149926 - 财政年份:2010
- 资助金额:
$ 29.36万 - 项目类别:
The Function of EZH2 in Estrogen Receptor Negative Breast Cancer in Women of Af
EZH2在AF女性雌激素受体阴性乳腺癌中的作用
- 批准号:
8307505 - 财政年份:2010
- 资助金额:
$ 29.36万 - 项目类别:
The Function of EZH2 in Estrogen Receptor Negative Breast Cancer in Women of Af
EZH2在AF女性雌激素受体阴性乳腺癌中的作用
- 批准号:
8014602 - 财政年份:2010
- 资助金额:
$ 29.36万 - 项目类别:
The Function of EZH2 in Estrogen Receptor Negative Breast Cancer in Women of Af
EZH2在AF女性雌激素受体阴性乳腺癌中的作用
- 批准号:
8707400 - 财政年份:2010
- 资助金额:
$ 29.36万 - 项目类别:
Role of CCN6 (WISP3) in the Progression and Metastasis of Breast Cancer.
CCN6 (WISP3) 在乳腺癌进展和转移中的作用。
- 批准号:
8777055 - 财政年份:2008
- 资助金额:
$ 29.36万 - 项目类别:
Role of CCN6 (WISP3) in the progression and metastasis of breast cancer
CCN6 (WISP3) 在乳腺癌进展和转移中的作用
- 批准号:
7529379 - 财政年份:2008
- 资助金额:
$ 29.36万 - 项目类别:
Role of CCN6 (WISP3) in the progression and metastasis of breast cancer
CCN6 (WISP3) 在乳腺癌进展和转移中的作用
- 批准号:
10447058 - 财政年份:2008
- 资助金额:
$ 29.36万 - 项目类别:
Role of CCN6 (WISP3) in the progression and metastasis of breast cancer
CCN6 (WISP3) 在乳腺癌进展和转移中的作用
- 批准号:
10676901 - 财政年份:2008
- 资助金额:
$ 29.36万 - 项目类别:
Role of CCN6 (WISP3) in the progression and metastasis of breast cancer
CCN6 (WISP3) 在乳腺癌进展和转移中的作用
- 批准号:
7903858 - 财政年份:2008
- 资助金额:
$ 29.36万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 29.36万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 29.36万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 29.36万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 29.36万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 29.36万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 29.36万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 29.36万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 29.36万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 29.36万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 29.36万 - 项目类别:
Research Grant